The proposed facility will be making Foot and Mouth disease (FMD) and other emerging diseases. The facility will create total employment for around 750 people. The facility is intended to be a state-of-art fully integrated biosafety level 3 (BSL-3) for drug substance (DS) production and respective fill-finish.
